Biobeat Technologies appoints Raymond Cohen as board chairman

Biobeat Technologies Ltd., a medical device company specializing in wearable blood pressure monitoring systems, announced the appointment of Raymond W. Cohen as Chairman of the Board of Directors.

The Israel-based company has developed an FDA-cleared patch device that monitors multiple physiological parameters including continuous cuff-less ambulatory blood pressure, oxygen saturation, respiration rate, pulse rate, heart rate variability, ECG, temperature and cardiac output. The device transmits patient data to a cloud-based system for analysis.

Cohen brings over four decades of life science industry experience to the role. He co-founded and served as CEO of Axonics, Inc. (NASDAQ: AXNX), a neuromodulation device company that went public in 2018 and was acquired by Boston Scientific for $3.7 billion in November 2024. Under his leadership, Axonics generated over $1 billion in revenue within four years of commercial launch.

Cohen also served as chairman of SoniVie Ltd., an Israeli renal denervation company that was sold to Boston Scientific for $600 million in March 2025.

"Ray's extensive track record in leading, financing and scaling medical technology companies will be invaluable as we look to capitalize on our unique ambulatory technology," said Arik Ben Ishay, co-founder and CEO of Biobeat.

Cohen currently serves on the boards of several healthcare companies, including Kestra Medical Technologies (NASDAQ: KMTS), InspireMD (NASDAQ: NSPR), and RxSight (NASDAQ: RXST). He also works as a venture partner with Paris-based Andera Partners and Beijing-based Sherpa Capital Partners.

Biobeat operates from Israel with offices in Boca Raton, Florida. The company's technology aims to provide continuous blood pressure monitoring through a small patch device, offering an alternative to traditional cuff-based ambulatory blood pressure monitoring systems.

You May Also Be Interested In

• Cerebras CEO says investors misunderstood margin guidance
• Fortinet adds Derek Kan to its board of directors
• Ian Wendler to retire from Jewett-Cameron board by July 31